Randomized Trials for Esophageal, Liver, Pancreas, and Rectal Cancers

Christopher L. Hallemeier(Mayo Clinic in Arizona), Salma K. Jabbour(Rutgers, The State University of New Jersey), F. Huguet(Sorbonne Université), Jordan Kharofa(Medical College of Wisconsin), Jeffrey R. Olsen(University of Colorado Denver), Michael Buckstein(Icahn School of Medicine at Mount Sinai), Diana Tait(Royal Marsden NHS Foundation Trust), Christopher J. Anker(University of Vermont)
International Journal of Radiation Oncology*Biology*Physics
January 8, 2021
10.1016/j.ijrobp.2020.09.033
Cited by 0

Related Papers

Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Clinical Features and Outcome in North American Adults With Moyamoya Phenomenon
|Stroke|2006|337
Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology
|International Journal of Radiation Oncology*Biology*Physics|2020|314
Oesophageal cancer
|The Lancet|2024|265